Written by: Nicky, Foresight News
The token BIO of Bio Protocol has recently performed impressively. According to Bitget data, the price of BIO started at $0.056 on August 6, 2025, and surged to a peak of $0.2081 on August 22, with an increase of over 270% during this period.
Currently, the staking scale of BIO has reached approximately 174 million tokens, accounting for about 9.3% of the total circulation of 1.854 billion tokens. At the same time, BIO has been listed on several mainstream exchanges, including Binance, Coinbase, and Bithumb.
At the end of 2024, the DeSci boom lasted only a few months. After BIO was listed on Binance, its token performance was described as a 'disaster,' dropping from a historic high of $0.8 reached shortly after launch, to hovering around $0.05 by August 2025, over 90% down from its peak. So what exactly revived BIO?
Tracing back to the project's origin, on November 8, 2024, Binance Labs (now YZi Labs) announced its investment in Bio Protocol. Although the details of the investment were not disclosed, this move marked mainstream capital's recognition of the DeSci track.
As a representative project of the DeSci track, the core goal of Bio Protocol is to 'transform the funding and commercialization model of early biotech research' and build a network of biotechnology DAOs.
By leveraging blockchain technology, global scientists, patients, and investors can collectively participate in new drug development, addressing the pain points of traditional research where 'funding is concentrated in large pharmaceutical companies, and results are closed off.' This helps global participants fund and collaborate on new drug development, especially for rare diseases, longevity research, and emerging health issues.
On June 3, 2025, the DeSci project token PYTHIA surged from $0.0168 to $0.122 on August 14, with an increase of 626%.
On July 31, 2025, Coinbase simultaneously listed the tokens BIO and RSC of two DeSci projects, marking DeSci's return to the attention of the mainstream Western digital currency market.
Since then, the token VITA of the DeSci project VitaDAO has continued to rise from $1.17 on August 1 to a peak of $2.22 on August 22, with a total increase of 89%. The token NEURON of Cerebrum DAO also performed excellently in August, with an increase of over 180% that month. At the same time, the token CRYO of CryoDAO saw an increase of over 200%, the token GROW of ValleyDAO increased by 76%, and the token HAIR of HairDAO increased by 67.5% this month. This indicates that DeSci is experiencing a revival.
Aubrai: How AI scientists are rewriting the rules of longevity research?
Entering 2025, Bio Protocol accelerated its iteration. On August 21, Bio Protocol, in conjunction with VitaDAO, launched its first BioAgent Launch project Aubrai, marking the official implementation of its 'decentralized research agency' plan. This sale lasted only 24 hours, with users participating by staking BioXP and investing in BIO tokens, and the TGE of the token AUBRAI will take place on August 25.
The tokenomics of AUBRAI have now been announced, with a total supply of 2 million tokens. The token distribution is: 20% for sale, 6% for liquidity pools, 15% for treasury, 20.1% allocated to initial funders, 10% allocated to the LEV Foundation, 22% allocated to VitaDAO, and 6.9% allocated to Bio Protocol.
Aubrai originates from the private lab data of longevity research pioneer Dr. Aubrey de Grey, who proposed the 'Strategies for Engineered Negligible Senescence' (SENS), aimed at preventing age-related diseases by repairing damage to aging cells. He holds a Bachelor's degree in Computer Science and a PhD in Biology from Cambridge University and has authored works such as (The Mitochondrial Free Radical Theory of Aging) (1999) and (Ending Aging) (2007).
de Grey currently serves as the chair and chief scientific officer of the LEV Foundation. The foundation focuses on longevity research, and its flagship project 'Robust Mouse Rejuvenation' tests late-stage intervention therapy combinations through large-scale mouse lifespan experiments. These experiments collaborate with Ichor Life Sciences, emphasizing damage repair methods while avoiding gene editing and other early interventions to accelerate clinical translation to humans.
Another LEV project 'Transplants on Demand' explores tissue engineering, funding Keinice Bio's cryopreservation technology that uses supercooled helium to achieve vitrification preservation of organs. This avoids the toxicity issues associated with traditional cryoprotectants, aiming to provide 'ready-to-use' young organ replacements to combat organ failure caused by aging.
The LEV Foundation also supports the Alliance for Longevity Initiatives, a 501(c)(4) non-profit organization aimed at promoting U.S. government policy support for longevity research. This is achieved by collaborating with relevant experts to raise public awareness of age-related chronic diseases and advocating for national funding.
Through this research, its private laboratory has accumulated thousands of unpublished research notes, internal experimental data, and collective knowledge in the global longevity field. These 'private research assets,' once limited to core team use, are now integrated by Aubrai as training data.
In practical applications, Aubrai has restructured de Grey's team's workflow. It manages over a dozen complex longevity research projects, compressing manual reviews that originally took weeks into just days. It also identifies dosage conflicts, time mismatches, and hidden biases, and even uncovers new problems unnoticed by the team.
According to the official roadmap, Aubrai has currently received joint funding from Bio Protocol and VitaDAO for the RMR2 pilot study, aimed at validating candidate interventions and optimizing administration methods; community scientists can experience its collaborative capabilities as 'co-scientists' through a closed beta version CHAT UI. At the same time, the wallet supports a self-hosted EOA wallet built on the Coinbase Developer Platform, with limited transaction authorization features.
In future plans, Aubrai will launch a semi-autonomous agent in the fourth quarter of 2025 (integrating Base AgentKit, supporting full transaction execution and financial autonomy), and open the FAILURE DB database (recording negative outcomes and design flaws to avoid repeated mistakes), ultimately achieving 'fully autonomous research' — a complete scientific output process from hypothesis generation, experimental design to wet lab execution and paper publication.
V2 Upgrade: Building an efficient cycle of 'Research - Capital'
Aubrai's launch relies on the support of the Bio Protocol V2 version. Its V2 version adopts the 'launch and grow' concept, achieving sustainable growth through a community-driven launchpad.
Undervalued launch: Referring to platforms like Pump.fun, the project's initial valuation dropped to $205,000 FDV, with 37.5% of the tokens sold directly, and each user allowed to subscribe to a maximum of 0.5% of the total tokens sold;
Sustainable liquidity: All funds raised (BIO tokens) after the initial launch will automatically generate an LP pool, combined with 12.5% of the supply tokens. A 1% fee will be charged on each transaction in the secondary market (70% goes to the project treasury, 30% to the protocol), forming a positive cycle of 'active trading — increased research funding — advancement of results — renewed market enthusiasm';
Points incentive mechanism: Users can earn BioXP points by staking, governance voting, community dissemination, participating in new launch projects, etc. The points can be used to participate in quota subscriptions for undervalued projects.
The implementation of these mechanisms has upgraded Bio Protocol from a 'research financing platform' to a 'research ecosystem operating system,' not only solving funding issues but also enhancing the efficiency of research results through community incentives and automation tools.
The 'long-termism' and future of DeSci
The market performance of BIO and the launch of Aubrai have brought the DeSci track back into public view. However, challenges in this field have never disappeared: long research cycles (even if Aubrai accelerates experiments, longevity therapies still take years to move from the lab to clinical trials), short market patience (crypto investors are accustomed to 'quick rises and falls'), and regulatory uncertainty (high compliance costs involved in human trials).
In this regard, Binance founder Zhao Changpeng stated in an exclusive interview with Foresight News: 'DeSci and meme coins are completely two extremes. DeSci projects have long cycles, while investors in the digital currency industry generally have shorter attention spans. Meme coins are very popular, and such projects are overlooked. But in the long run, these projects contribute greatly to humanity and society, and I believe they will develop in the future, just uncertain when.'
